Table 2 Primary and secondary outcomes between DHEA+ and DHEA - control groups
|  | DHEA + group | DHEA- control group | Effect estimatea | p-value |
|---|---|---|---|---|
(n = 28) | (n = 24) | (95% CI) | ||
Clinical outcomes | ||||
 Clinical pregnancy, n (%) | 2 (7.1) | 3 (12.5) | 0.57 (0.10–3.14) | 0.652 |
 No. of oocytes retrieved, mean (SD) | 5.2 (2.9) | 4.5 (3.6) | 0.7 (-1.4 to 2.9) | 0.507 |
 No. of metaphase II oocytes, mean (SD) | 4.0 (2.5) | 3.5 (2.2) | 0.6 (-1.0 to 2.1) | 0.459 |
 No. of embryos, mean (SD) | 2.7 (2.4) | 2.3 (1.8) | 0.4 (-1.1 to 1.8) | 0.601 |
Embryos transferred, n (%) | ||||
 0 | 5 (23.8) | 3 (17.7) | 1 |  |
 1 | 9 (42.9) | 5 (29.4) | 1.03 (0.53 to 2.00) | 1 |
 2 | 7 (33.3) | 9 (52.9) | 0.78 (0.44 to 1.39) | 0.667 |
Hormonal outcomesb | ||||
 DHEA-S (µg/ml) | 870.73 (96.00–3385.57) | 182.45 (47.25–589.19) | 4.77 (2.83 to 8.04) |  < 0.001 |
 Free Testosterone (pg/ml) | 87.68 (19.54–457.86) | 25.50 (11.56–202.89) | 3.44 (2.12 to 5.59) |  < 0.001 |
 Estradiol (× 105) (pg/ml) | 17.2 (6.15–137.00) | 14.7 (2.15–32.5) | 1.17 (0.67 to 2.02) | 0.571 |
 AMH (ng/ml) | 1.37 (0.21–12.60) | 1.56 (0.39–6.12) | 0.88 (0.45 to 1.70) | 0.687 |
 IGF1 (ng/ml) | 0.23 (0.01–18.84) | 0.23 (0.08–14.22) | 0.99 (0.37 to 2.63) | 0.976 |